Skip to content
DataLookout
Menu

TroFuse-027NCT06637423

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 23 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary completion date changed from estimate of Mar 14, 2029 to Sep 30, 2026
    • Enrollment target: estimated 32 to confirmed 35
    • Site details revised at 13 of 13 sites
  2. Minor Site details revised at 8 of 13 sites
  3. Notable Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 5 of 14 entries
    • Study sites revised (13)
  4. Minor Study sites revised (13)v23
  5. Minor Site contacts updated at 1 of 13 sitesv22
  6. Notable Primary and study completion dates pushed to Mar 14, 2029
    • Site details revised at 3 of 13 sites
    v21
  7. Minor Study sites revised (13)v20
  8. Minor Site contacts updated at 1 of 13 sitesv19
  9. Minor Site contacts updated at 1 of 13 sitesv17
  10. Minor Study sites: 12 to 13v16
  11. Minor Study sites: 11 to 12v14
  12. Minor Study sites: 10 to 11v13
  13. Minor Study sites: 9 to 10v12
  14. Minor Study sites: 8 to 9v11
  15. Minor Study sites: 6 to 8v10
  16. Minor Study sites: 5 to 6v9
  17. Notable Eligibility criteria expanded, about 7 words
    • Interventions: Sacituzumab tirumotecan (Drug) to Rescue medication (Drug), Sacituzumab tirumotecan (Drug), Supportive care measures (Drug)
    v8
  18. Minor Study sites: 4 to 5v7
  19. Minor Study sites: 3 to 4
    • Study completion date: Nov 30, 2026 to Jul 31, 2028
    v6
  20. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Dec 26, 2024 to Dec 20, 2024
    v5
  21. Notable Eligibility criteria expanded, about 63 words
    • Secondary endpoints: 5 to 14
    v4
  22. Minor Start date: Nov 27, 2024 to Dec 26, 2024v3
  23. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Dose Limiting Toxicity (DLT)
Timeframe: Up to approximately 7 weeks
Number of Participants Experiencing an Adverse Event (AE)
Timeframe: Up to approximately 10 weeks
Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)
Timeframe: Up to approximately 6 weeks

Secondary (14)

Area Under the Serum Concentration-Time Curve (AUC) of sacituzumab tirumotecan (sac-TMT) Antibody-Drug Conjugate (ADC)
Maximum Serum Concentration (Cmax) of sac-TMT ADC
Minimum Serum Concentration (Cmin) of sac-TMT ADC
Serum Apparent terminal half-life (t½) of sac-TMT ADC
Serum AUC of sac-TMT Total Antibody (TAb)
Show 9 moreShow less
Serum Cmax of sac-TMT Tab
Serum Cmin of sac-TMT Tab
Serum t½ of sac-TMT Tab
Plasma AUC of sac-TMT payload
Plasma Cmax of sac-TMT payload
Plasma Cmin of sac-TMT payload
Plasma t½ of sac-TMT payload
Complete Response Rate (CRR)
Duration of Complete Response (DCR)

Arms and interventions

Sacituzumab tirumotecanExperimental

Participants receive intravesical Sacituzumab Tirumotecan for 6 weeks

Drugs: Sacituzumab tirumotecan, Rescue medication, Supportive care measures

Sites

13 sites in 6 countries

United States 4, France 3, Canada 2, Spain 2, Netherlands 1, United Kingdom 1